Advances in laboratory medicine最新文献

筛选
英文 中文
False HbA1c value due to a rare variant of hemoglobin Petie Salpetriere coinherited with alpha thalassemia. 由于一种罕见的与α地中海贫血共遗传的血红蛋白Petie Salpetriere变异导致的假HbA1c值。
IF 1.1
Advances in laboratory medicine Pub Date : 2024-10-09 eCollection Date: 2024-12-01 DOI: 10.1515/almed-2024-0037
Esperanza Lepe Balsalobre, Gema María Varo Sánchez, Marta Rico Rodríguez, Sandra Fuentes Cantero
{"title":"False HbA<sub>1c</sub> value due to a rare variant of hemoglobin Petie Salpetriere coinherited with alpha thalassemia.","authors":"Esperanza Lepe Balsalobre, Gema María Varo Sánchez, Marta Rico Rodríguez, Sandra Fuentes Cantero","doi":"10.1515/almed-2024-0037","DOIUrl":"10.1515/almed-2024-0037","url":null,"abstract":"<p><strong>Objectives: </strong>To describe a variant hemoglobin that interferes with HbA<sub>1c</sub> analysis by cation exchange HPLC.</p><p><strong>Case presentation: </strong>A 78 years-old Spanish male patient visited the Internal Medicine Clinic for a routine check-up, with HbA<sub>1c</sub> included to screen for diabetes. He had suffered hypertension and dyslipidemia, and the patient had no previous symptoms suggestive of diabetes such as hyperglycemia, weight loss, polydipsia, polyuria or tiredness. Diabetes screening by HbA<sub>1c</sub> measurement was assessed using cation exchange HPLC and an immunoassay point-of-care analyzer. Routine hemoglobinopathy screening was performed including CBC, HbF and HbA<sub>2</sub> measurement by cation exchange HPLC and capillary electrophoresis (CE). Further variant characterization was undertaken by DNA sequencing. Discordant HbA<sub>1c</sub> results were obtained for our subject, with elevated HbA<sub>1c</sub> of 52 mmol/mol measured by cation exchange HPLC and a normal level of 34 mmol/mol by immunoassay. Abnormal HbA<sub>1c</sub> peak shape prompted hemoglobinopathy screening to investigate potential variant interference. A globin gene analysis was performed, and the results showed a variant hemoglobin named 'Hb Petie Salpetriere'. This variant arises from a Val → Phe substitution due to a mutation of c.103G>T of the beta-globin gene [BETA34 (B16) Val>Phe; HBB:c.103G>T].</p><p><strong>Conclusions: </strong>This is the first reported case involving the Hb Petie Salpetriere variant in a Spanish patient. The present results show that the Hb Petie Salpetriere variant can affect the results of HbA<sub>1c</sub> analysis through ion-exchange HPLC, but not that obtained from the latex agglutination immunoassay. Only ion-exchange HPLC suggested the presence of the Hb variant in this case, suggesting that a careful review of the resulting chromatogram might reveal a potential variant.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"5 4","pages":"447-450"},"PeriodicalIF":1.1,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11661534/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Interferencia por macrocomplejos B12: hacia una detección eficaz e interpretación correcta de la hipo e hipervitaminemia. B12干扰:对低血压和高维生素血症的有效检测和正确解释。
IF 1.1
Advances in laboratory medicine Pub Date : 2024-09-27 eCollection Date: 2024-12-01 DOI: 10.1515/almed-2024-0126
Jose Antonio Delgado, María I Pastor, Gemma Costa, Nuria Márquez, Josep Miquel Bauça
{"title":"Interferencia por macrocomplejos B12: hacia una detección eficaz e interpretación correcta de la hipo e hipervitaminemia.","authors":"Jose Antonio Delgado, María I Pastor, Gemma Costa, Nuria Márquez, Josep Miquel Bauça","doi":"10.1515/almed-2024-0126","DOIUrl":"10.1515/almed-2024-0126","url":null,"abstract":"","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"5 4","pages":"394-401"},"PeriodicalIF":1.1,"publicationDate":"2024-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11661544/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Farmacogenética del cáncer colorrectal en un hospital terciario de Valencia. 巴伦西亚三级医院结肠直肠癌的药物遗传学。
IF 1.1
Advances in laboratory medicine Pub Date : 2024-09-24 eCollection Date: 2024-12-01 DOI: 10.1515/almed-2024-0063
Ana Comes-Raga, Luis Sendra, Goitzane Marcaida-Benito, Salvador F Aliño, María José Herrero
{"title":"Farmacogenética del cáncer colorrectal en un hospital terciario de Valencia.","authors":"Ana Comes-Raga, Luis Sendra, Goitzane Marcaida-Benito, Salvador F Aliño, María José Herrero","doi":"10.1515/almed-2024-0063","DOIUrl":"10.1515/almed-2024-0063","url":null,"abstract":"","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"5 4","pages":"432-438"},"PeriodicalIF":1.1,"publicationDate":"2024-09-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11661546/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Urine analysis in monoclonal gammopathies at diagnosis: settling cut-off values. 单克隆伽玛病诊断时的尿液分析:确定临界值。
IF 1.1
Advances in laboratory medicine Pub Date : 2024-09-23 eCollection Date: 2024-12-01 DOI: 10.1515/almed-2024-0045
Mònica Vidal-Pla, Elisa Nuez-Zaragoza, Indira Bhambi, Vicente Aguadero
{"title":"Urine analysis in monoclonal gammopathies at diagnosis: settling cut-off values.","authors":"Mònica Vidal-Pla, Elisa Nuez-Zaragoza, Indira Bhambi, Vicente Aguadero","doi":"10.1515/almed-2024-0045","DOIUrl":"10.1515/almed-2024-0045","url":null,"abstract":"<p><strong>Objectives: </strong>Laboratory testing has an extensive role in the diagnosis of monoclonal gammopathies. Since the last updates of the International Myeloma Working Group (IMWG) guidelines for the diagnosis of monoclonal gammopathies, debate has arisen as to whether urine analysis remains relevant for the diagnosis of these entities.</p><p><strong>Methods: </strong>We carried out a retrospective study with data from 132 patients with a newly diagnosed serum M-protein. Patients were divided into two groups depending on the presence of M-protein in urine and different variables were recorded and statistically compared between groups.</p><p><strong>Results: </strong>The aim of the study was to find a serum M-protein cut-off value under which urine analysis could be avoided in the first laboratory diagnosis. The results show that when the concentration of serum M-protein is ≤3.5 g/L and eGFR is >30 mL/min/1.73 m<sup>2</sup> (sensitivity (S): 100 %, specificity (Sp): 49 %, negative-predictive value (NPV): 100 %) the probability of finding M-protein in urine is negligible. Patients with alpha heavy chain have a higher probability of having M-protein in urine. Thus, when the heavy chain of the M-protein is gamma or mu, serum cut-off value can be raised up to ≤4.9 g/L (S: 97 %, Sp: 52 %, NPV: 98 %).</p><p><strong>Conclusions: </strong>Settling these two cut-off values when a new M-protein is discovered could avoid a significant number of urine analyses, optimizing laboratory and healthcare resources.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"5 4","pages":"439-442"},"PeriodicalIF":1.1,"publicationDate":"2024-09-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11661531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878729","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
T315I - a gatekeeper point mutation and its impact on the prognosis of chronic myeloid leukemia. T315I -一个守门人点突变及其对慢性髓性白血病预后的影响。
IF 1.1
Advances in laboratory medicine Pub Date : 2024-09-16 eCollection Date: 2024-12-01 DOI: 10.1515/almed-2024-0069
Bushra Kaleem, Sadaf Shahab, Tahir Sultan Shamsi
{"title":"T315I - a gatekeeper point mutation and its impact on the prognosis of chronic myeloid leukemia.","authors":"Bushra Kaleem, Sadaf Shahab, Tahir Sultan Shamsi","doi":"10.1515/almed-2024-0069","DOIUrl":"10.1515/almed-2024-0069","url":null,"abstract":"<p><strong>Objectives: </strong><i>BCR-ABL</i> kinase domain mutations are an important cause of resistance to tyrosine kinase inhibitors (TKIs) in chronic myeloid leukaemia (CML) of which T315I is the most treatment-resilient. This study aimed to observe the frequency of T315I and its impact on disease prognosis in terms of progression and survival.</p><p><strong>Methods: </strong>Patients with a response which categorized them into warning zone/or who failed to respond to their TKI treatment completely as per the European LeukemiaNet (ELN) were labeled as non-responders. They were assessed for T315I mutation using amplification refractory mutation system-polymerase chain reaction (ARMS-PCR) and validated via sequencing. Patients were then longitudinally followed for 96 months for the prognostic impact of the mutation.</p><p><strong>Results: </strong>Of the 102 non-responders, T315I mutation was detected in 21.6 % of patients with a female preponderance. Almost 59 % of mutation-harbouring patients were labelled as low Sokal risk at baseline. The disease progression into the blastic phase was reported in 58.8 % of mutation-harbouring patients. Overall survival (study period: 96 months) was 81.8 % in patients harbouring T315I mutation. Patients in the blastic phase had significant odds of harbouring T315I mutation.</p><p><strong>Conclusions: </strong>Sub-optimal response or failure to TKI treatment indicates the development of resistance due to the presence of T315I mutation or other mutation(s). Early identification will help redirect the patient's treatment.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"5 4","pages":"412-417"},"PeriodicalIF":1.1,"publicationDate":"2024-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11661532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142878728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison between a new device for the semen quality analysis and the manual microscopic evaluation in a not specialistic clinical laboratory. 一种新型精液质量分析装置与非专业临床实验室人工显微评价的比较。
IF 1.1
Advances in laboratory medicine Pub Date : 2024-08-26 eCollection Date: 2024-12-01 DOI: 10.1515/almed-2024-0089
Erika Jani, Margherita Bozzola, Elmar Marco Zagler, Vincenzo Roccaforte, Massimo Daves
{"title":"Comparison between a new device for the semen quality analysis and the manual microscopic evaluation in a not specialistic clinical laboratory.","authors":"Erika Jani, Margherita Bozzola, Elmar Marco Zagler, Vincenzo Roccaforte, Massimo Daves","doi":"10.1515/almed-2024-0089","DOIUrl":"10.1515/almed-2024-0089","url":null,"abstract":"<p><strong>Objectives: </strong>Semen analysis investigates different parameters of human semen with a high relevance in fertility workup, confirmation of sterility by post vasectomy, in pathologies follow-up such as varicocele and in all cases where sperm preservation is required. Manually seminal fluid examination is characterized by poor reproducibility. Aim of this study was to evaluate the performance of an automatic device in semen analysis by comparing its results with those obtained with the manual microscopy.</p><p><strong>Materials: </strong>Fifty samples (age 18-59 years) were analyzed simultaneously by the manual and automated method. Manual analysis was performed by at least two experienced operators. Concentration and motility were determined by means of standard manual analysis and by the automated LensHooke™ analyzer following the last WHO guidelines.</p><p><strong>Results: </strong>We compared the concentration (million/mL) of spermatozoa obtained from manual and instrumental count and different classifications obtained: normal, oligospermic, cryptospermic and azoospermic samples. The Wilcoxon test does not show a statistically significant difference. The Bland-Altman plot showed a slightly higher value for the manual count. Second, we compared the morphology and the samples classification in morphological normal and abnormal. Third, spermatozoa motility obtained from the manual and instrumental count was compared with a different classification in normal total motility and asthenozoospermia. Statistical tests showed respectively for morphology and motility a moderate and a very good agreement.</p><p><strong>Conclusions: </strong>Our study demonstrates that the LensHooke™ shows an acceptable agreement with the manual microscopic seminal fluid evaluation. The use of this simple device could help to standardize reports in non specialistic laboratories.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"5 4","pages":"402-406"},"PeriodicalIF":1.1,"publicationDate":"2024-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11661535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142877794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sperm recovery from urine in men with retrograde ejaculation. 男性逆行射精从尿液中恢复精子。
IF 1.1
Advances in laboratory medicine Pub Date : 2024-08-22 eCollection Date: 2024-12-01 DOI: 10.1515/almed-2024-0109
Ernesto Veiga Álvarez, Nuria Zopeque García, Javier M Gutiérrez Romero, Pilar Reimundo Díaz-Fierros, María D Lozano Arana, Tamara Rodríguez Pérez, Javier Sánchez Álvarez, Guadalupe Bueno Rodríguez, Vanesa Castañón Bernardo, María J Moyano Gallego
{"title":"Sperm recovery from urine in men with retrograde ejaculation.","authors":"Ernesto Veiga Álvarez, Nuria Zopeque García, Javier M Gutiérrez Romero, Pilar Reimundo Díaz-Fierros, María D Lozano Arana, Tamara Rodríguez Pérez, Javier Sánchez Álvarez, Guadalupe Bueno Rodríguez, Vanesa Castañón Bernardo, María J Moyano Gallego","doi":"10.1515/almed-2024-0109","DOIUrl":"https://doi.org/10.1515/almed-2024-0109","url":null,"abstract":"<p><strong>Introduction: </strong>Retrograde ejaculation (RE) consists of the reflux backwards, towards the bladder, of the ejaculate, during the emission phase of ejaculation, causing a total or partial absence of sperm emission, with the consequent diversion of semen into the bladder during the emission phase of ejaculation. Evaluating the ejaculate may not be sufficient for identifying RE in some patients. Hence, the management of infertility may involve the use of invasive methods such as epididymal fluid retrieval or testicular biopsy.</p><p><strong>Content: </strong>This paper defines RE and methods for its diagnosis. A description is also provided of the techniques used for the detection of sperm in post-ejaculatory urine (PEU), the preparation and retrieval of sperm from urine and their subsequent use in assisted reproductive techniques.</p><p><strong>Summary: </strong>The diagnosis of RE is based on the detection of spermatozoa in PEU in patients with aspermia or oligozoospermia and low or normal seminal volume. Although the presence of sperm in PEU could be sufficient for a diagnosis of RE, there is a lack of consensus regarding the diagnostic criteria for PEU, and the literature available is very limited. A correct diagnosis of RE allows the use of PEU for recovering sperm and its subsequent use in assisted human reproduction techniques, thus avoiding invasive techniques.</p><p><strong>Outlook: </strong>A significant number of patients with RE may remain undiagnosed. Therefore, it is essential to conduct an RE study in patients with suspicion, through the analysis of PEU, and to properly interpret the results for accurate diagnosis.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"5 4","pages":"356-365"},"PeriodicalIF":1.1,"publicationDate":"2024-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11704877/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142959827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Valor del análisis de péptido natriurético en el diagnóstico y prevención de la insuficiencia cardíaca en poblaciones de alto riesgo. 钠尿肽分析在诊断和预防高危人群心力衰竭中的价值。
IF 1.1
Advances in laboratory medicine Pub Date : 2024-08-20 eCollection Date: 2024-09-01 DOI: 10.1515/almed-2024-0122
Damien Gruson
{"title":"Valor del análisis de péptido natriurético en el diagnóstico y prevención de la insuficiencia cardíaca en poblaciones de alto riesgo.","authors":"Damien Gruson","doi":"10.1515/almed-2024-0122","DOIUrl":"https://doi.org/10.1515/almed-2024-0122","url":null,"abstract":"","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"5 3","pages":"233-235"},"PeriodicalIF":1.1,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11381943/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The value of natriuretic peptide testing for the diagnosis and prevention of heart failure in high-risk populations. 钠尿肽检测对诊断和预防高危人群心力衰竭的价值。
IF 1.1
Advances in laboratory medicine Pub Date : 2024-08-19 eCollection Date: 2024-09-01 DOI: 10.1515/almed-2024-0121
Damien Gruson
{"title":"The value of natriuretic peptide testing for the diagnosis and prevention of heart failure in high-risk populations.","authors":"Damien Gruson","doi":"10.1515/almed-2024-0121","DOIUrl":"https://doi.org/10.1515/almed-2024-0121","url":null,"abstract":"","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"5 3","pages":"231-232"},"PeriodicalIF":1.1,"publicationDate":"2024-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11381084/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of laboratory involvement in the characterization of B12 hypervitaminosis in clinical practice. 实验室参与 B12 高维生素症定性对临床实践的影响。
IF 1.1
Advances in laboratory medicine Pub Date : 2024-08-14 eCollection Date: 2024-09-01 DOI: 10.1515/almed-2024-0098
Sara Fernández-Landázuri, Ramón Baeza-Trinidad, Iván Bernardo González
{"title":"Impact of laboratory involvement in the characterization of B12 hypervitaminosis in clinical practice.","authors":"Sara Fernández-Landázuri, Ramón Baeza-Trinidad, Iván Bernardo González","doi":"10.1515/almed-2024-0098","DOIUrl":"https://doi.org/10.1515/almed-2024-0098","url":null,"abstract":"<p><strong>Objectives: </strong>Unexplained B12 hypervitaminosis (HB12) in asymptomatic patients leads to a cascade of medical consultations and diagnostic tests aimed at determining its etiology. The objective of this study was to assess the efficacy of the laboratory getting involved in the detection and elimination of immune complexes with vitamin B12 in clinical practice and its economic impact.</p><p><strong>Methods: </strong>A retrospective longitudinal study was undertaken to assess the laboratory strategy of detecting B12 macrovitamin (macro-B12) in patients with HB12 >1,000 pg/mL. The clinical characteristics of patients with HB12 referred to Internal Medicine (IM) in the pre- and post-implantation period of the new strategy were compared. Additionally, the healthcare costs of one-year follow-up were estimated.</p><p><strong>Results: </strong>The prevalences of HB12 in the pre- and post-implantation period were 3.9 % and 3 %, respectively. Macro-B12 explained 25 % of the HB12 cases initially detected. A 41 % reduction was observed in the number of patients with HB12 after the implantation of the new strategy, thereby resulting in a cost reduction of 5,000 €.</p><p><strong>Conclusions: </strong>The laboratory intervention for the detection of macro-B12 provides clear economic and clinical benefits in clinical practice.</p>","PeriodicalId":72097,"journal":{"name":"Advances in laboratory medicine","volume":"5 3","pages":"313-319"},"PeriodicalIF":1.1,"publicationDate":"2024-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380925/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142302197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信